CochLear (OTCMKTS:CHEOY) versus Biodesix (NASDAQ:BDSX) Head-To-Head Review

CochLear (OTCMKTS:CHEOY) and Biodesix (NASDAQ:BDSX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Earnings & Valuation

This table compares CochLear and Biodesix”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CochLear	$1.53 billion	7.43	$251.85 million	N/A	N/A
Biodesix	$71.32 million	0.76	-$42.93 million	($5.56)	-1.22

CochLear has higher revenue and earnings than Biodesix.

Institutional & Insider Ownership

21.0% of Biodesix shares are owned by institutional investors. 30.1% of Biodesix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for CochLear and Biodesix, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CochLear	0	3	0	2	2.80
Biodesix	1	1	4	0	2.50

Biodesix has a consensus price target of $32.50, suggesting a potential upside of 377.94%. Given Biodesix’s higher probable upside, analysts plainly believe Biodesix is more favorable than CochLear.

Risk and Volatility

CochLear has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Biodesix has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.

Profitability

This table compares CochLear and Biodesix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CochLear	N/A	N/A	N/A
Biodesix	-49.31%	-504.41%	-43.94%

Summary

CochLear beats Biodesix on 9 of the 13 factors compared between the two stocks.

About CochLear

Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.

About Biodesix

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.